Literature DB >> 15198927

Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis.

Midori Yamakawa1, Louis X Liu, Adam J Belanger, Taro Date, Takayuki Kuriyama, Mark A Goldberg, Seng H Cheng, Richard J Gregory, Canwen Jiang.   

Abstract

The hereditary von Hippel-Lindau (VHL) syndrome predisposes sufferers to highly vascularized tumors such as renal clear cell carcinoma (RCC) and central nervous system hemangioblastoma. In RCC4 and RCC786-0 VHL- cells with VHL mutations, the protein of hypoxia-inducible factor-1alpha (HIF-1alpha) is constitutively stabilized and the mRNA levels of HIF target genes, including vascular endothelial growth factor (VEGF), are elevated. However, the expression of angiopoietins in these cells and their involvement in angiogenesis are not well known. In this study, we compared the mRNA levels of angiopoietins in human kidney proximal tubule epithelial (RPTE) and RCC4 and RCC786-0 VHL- cells. In RPTE cells, angiopoietin-4 (Ang-4) expression was selectively induced by hypoxia or by expression of a hybrid form of HIF-1alpha. Under normoxic conditions, the mRNA levels of Ang-4 were higher in RCC4 and RCC786-0 VHL- than RPTE cells. Angiopoietin-1 expression was detectable in RCC4 and RCC786-0 VHL- cells but not RPTE cells. In RCC786-0 VHL+ cells, which were stably transfected with a wild-type copy of VHL, the mRNA levels of VEGF and Ang-4 were suppressed and the hypoxic response was restored. We also demonstrated that stimulation of endothelial tube formation by conditioned medium harvested from RCC4 cells was inhibited by a soluble Tie-2 receptor. These results suggest that the angiopoietin/Tie-2 system may participate in the angiogenic response to hypoxia in renal tissues and in tumor angiogenesis in renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198927     DOI: 10.1152/ajprenal.00028.2004

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  18 in total

1.  Characterization of the CXCR4 signaling in pancreatic cancer cells.

Authors:  Daniel D Billadeau; Subrha Chatterjee; Patricia Bramati; Raghavakaimal Sreekumar; Vijay Shah; Karen Hedin; Raul Urrutia
Journal:  Int J Gastrointest Cancer       Date:  2006

2.  Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data.

Authors:  Nirmalya Bandyopadhyay; Tamer Kahveci; Steve Goodison; Y Sun; Sanjay Ranka
Journal:  Adv Bioinformatics       Date:  2010-03-03

3.  Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases.

Authors:  Tianhong Pan; Eliza L S Fong; Mariane Martinez; Daniel A Harrington; Sue-Hwa Lin; Mary C Farach-Carson; Robert L Satcher
Journal:  Cancer Lett       Date:  2015-05-21       Impact factor: 8.679

Review 4.  Perspectives in drug development for metastatic renal cell cancer.

Authors:  Bristi Basu; Tim Eisen
Journal:  Target Oncol       Date:  2010-08-06       Impact factor: 4.493

Review 5.  Future directions in renal cell carcinoma: 2011 and beyond.

Authors:  Daniel C Cho; Michael B Atkins
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

Review 6.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

Review 7.  Glioma stem cell maintenance: the role of the microenvironment.

Authors:  John M Heddleston; Masahiro Hitomi; Monica Venere; William A Flavahan; Kenneth Yang; Youngmi Kim; Sana Minhas; Jeremy N Rich; Anita B Hjelmeland
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

9.  New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.

Authors:  C Lance Cowey; Guru Sonpavde; Thomas E Hutson
Journal:  Onco Targets Ther       Date:  2010-10-05       Impact factor: 4.147

Review 10.  VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Authors:  W Kimryn Rathmell; Shufen Chen
Journal:  Expert Rev Anticancer Ther       Date:  2008-01       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.